Low-molecular-weight heparin and cancer

Seminars in Thrombosis and Hemostasis

Volumn 26, Issue 3 SUPPL. 1, 2000, Pages 69-77

  Zacharski, L R ^a   Ornstein, D L ^a   Mamourian, A C ^a  

^a Department of Veterans Affairs Regional Office White River Junction   (United States)

Author keywords

Angiogenesis; Antineoplastic action; Cancer; Low molecular weight heparins

Indexed keywords

GROWTH FACTOR; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTEINASE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CLASSIFICATION; CANCER INHIBITION; CANCER STAGING; CLINICAL TRIAL; CONFERENCE PAPER; DRUG METABOLISM; DRUG RESPONSE; HUMAN; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LUNG NEOPLASMS; NEOPLASMS; RESEARCH DESIGN;

EID: 0033816996     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (58)

1. Heparin
2. Low-molecular-weight heparins
3. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients
4. Upper extremity deep venous thrombosis in cancer patients with venous access devices - Prophylaxis with a low molecular weight heparin (Fragmin)
5. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
6. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis
7. Low-molecular-weight heparin in the management of Trousseau's syndrome
8. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients
9. Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC) - A multicenter co-operative double-blind trial in comparison with heparin
10. Treatment of radiation-induced nervous system injury with heparin and warfarin
11. Low molecular weight hepatin stimulates megakaryocytopoiesis in bone-marrow transplantation patients
12. Proteoglycans as modulators of growth factor activities
13. Non-anticoagulant uses of heparin
14. Non-anticoagulant functions of heparin and heparin sulfate
15. The influence of anticlotting agents on transplantation and growth of tumor tissue
16. Heparin and cancer
17. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis
18. Peri-operative heparin: A possible adjuvant to surgery in colo-rectal cancer?
19. The influence of heparin and curable resection on the survival of colorectal cancer
20. Effect of perioperative low-dose heparin administration on the course of colon cancer
21. Perioperative heparin therapy inhibits late death from metastatic cancer
22. Subcutaneous heparin treatment increases survival in small cell lung cancer. 'Petites Cellules' Group
23. Blood coagulation and thrombosis in patients with ovarian malignancy
24. Glycosaminoglycans and their binding to biological macromolecules
25. Proteoglycans: Structure, function, and role in neoplasia
26. Proteoglycans: Structures and interactions
27. Glycosaminoglycan free chains. External plasma membrane components distinct from the membrane proteoglycans
28. Interactions of heparins in the vascular environment
29. Heparin and chemotherapy in the management of inoperable lung carcinoma
30. PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis
31. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer
32. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma
33. Tumor angiogenesis in pulmonary adenocarcinomas: Relationship with basic fibroblast growth factor, its receptor, and survival
34. Modulation of neoangiogenesis in bronchial preneoplastic lesions
35. Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis
36. Induction of hepatocyte growth factor in flbroblasts by tumor-derived factors affects invasive growth of tumor cells: In vitro analysis of tumor-stromal interactions
37. Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines
38. Heparin-binding epidermal growth factor-like growth factor and transforming growth factor-alpha in human non-small cell lung cancers
39. Expression of PDGF, IGF-II, bFGF and TGF-beta 1 in pulmonary adenocarcinoma
40. Isolation of a cDNA for a growth factor of vascular endothelial cells from human lung cancer ceils: Its identity with insulin-like growth factor II
41. Production of a motility factor by a newly established lung adenocarcinoma cell line
42. Reciprocal expression of pleiotrophin and midkine in normal versus malignant lung tissues
43. Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors
44. Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis
45. Activation of coagulation and angiogenesis in cancer: Immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer
46. Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues
47. Heparin, monocytes, and procoagulant activity
48. Tissue factor and plasminogen activator inhibitor type 2 expression in human stimulated monocytes is inhibited by heparin
49. Heparan sulfate proteoglycans mediate interleukin-7-dependent B lymphopoiesis
50. Synergistic induction of DNA strand breakage by cigarette tar and nitric oxide
51. Heparin and angiogenesis: A low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically
52. Basic-fibroblast-growth-factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin
53. Heparin oligosaccharides: Inhibitors of the biological activity of bFGF on Caco-2 cells
54. Advances in perfusion MR imaging
55. Low molecular weight heparin: Biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthetic management
56. Pathways of coagulation/fibrinolysis activation in malignancy
57. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties
58. Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival